Is Estrella Immunopharma Stock a Good Investment?
Estrella Immunopharma Investment Advice | ESLAW |
Not Rated
Examine Estrella Immunopharma Stock
Researching Estrella Immunopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if Estrella Immunopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Estrella Immunopharma's research are outlined below:
| Estrella Immunopharma is not yet fully synchronised with the market data | |
| Estrella Immunopharma generated a negative expected return over the last 90 days | |
| Estrella Immunopharma has high historical volatility and very poor performance | |
| Estrella Immunopharma has some characteristics of a very speculative penny stock | |
| Estrella Immunopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.31 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Estrella Immunopharma generates negative cash flow from operations | |
| Estrella Immunopharma has a frail financial position based on the latest SEC disclosures |
Estrella Immunopharma Quarterly Liabilities And Stockholders Equity |
|
Estrella Immunopharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.10) | (0.10) | |
| Return On Capital Employed | (0.18) | (0.18) | |
| Return On Assets | (0.10) | (0.10) | |
| Return On Equity | (0.14) | (0.15) |
Determining Estrella Immunopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Estrella Immunopharma is a good buy. For example, gross profit margin measures Estrella Immunopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Estrella Immunopharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Estrella Immunopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Estrella Immunopharma. Check Estrella Immunopharma's Beneish M Score to see the likelihood of Estrella Immunopharma's management manipulating its earnings.
Evaluate Estrella Immunopharma's management efficiency
The company has return on total asset (ROA) of (1.7475) % which means that it has lost $1.7475 on every $100 spent on assets. This is way below average. Estrella Immunopharma's management efficiency ratios could be used to measure how well Estrella Immunopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2025. Return On Capital Employed is likely to drop to -0.18 in 2025. At this time, Estrella Immunopharma's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 302.3 K in 2025, whereas Non Current Assets Total are likely to drop 0.00 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.23 | 1.29 | |
| Tangible Book Value Per Share | 1.23 | 1.29 | |
| Enterprise Value Over EBITDA | (65.28) | (68.54) | |
| Price Book Value Ratio | 8.39 | 8.81 | |
| Enterprise Value Multiple | (65.28) | (68.54) | |
| Price Fair Value | 8.39 | 8.81 | |
| Enterprise Value | 59.8 M | 51.9 M |
Evaluating the management effectiveness of Estrella Immunopharma allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Estrella Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta (0.09) |
Understand Estrella Immunopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Estrella Immunopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1436 | |||
| Market Risk Adjusted Performance | (1.21) | |||
| Mean Deviation | 21.84 | |||
| Semi Deviation | 19.51 | |||
| Downside Deviation | 26.89 | |||
| Coefficient Of Variation | 623.89 | |||
| Standard Deviation | 35.41 | |||
| Variance | 1253.58 | |||
| Information Ratio | 0.1575 | |||
| Jensen Alpha | 6.08 | |||
| Total Risk Alpha | 1.85 | |||
| Sortino Ratio | 0.2073 | |||
| Treynor Ratio | (1.22) | |||
| Maximum Drawdown | 206.52 | |||
| Value At Risk | (46.69) | |||
| Potential Upside | 77.4 | |||
| Downside Variance | 723.04 | |||
| Semi Variance | 380.59 | |||
| Expected Short fall | (32.55) | |||
| Skewness | 1.82 | |||
| Kurtosis | 5.64 |
| Risk Adjusted Performance | 0.1436 | |||
| Market Risk Adjusted Performance | (1.21) | |||
| Mean Deviation | 21.84 | |||
| Semi Deviation | 19.51 | |||
| Downside Deviation | 26.89 | |||
| Coefficient Of Variation | 623.89 | |||
| Standard Deviation | 35.41 | |||
| Variance | 1253.58 | |||
| Information Ratio | 0.1575 | |||
| Jensen Alpha | 6.08 | |||
| Total Risk Alpha | 1.85 | |||
| Sortino Ratio | 0.2073 | |||
| Treynor Ratio | (1.22) | |||
| Maximum Drawdown | 206.52 | |||
| Value At Risk | (46.69) | |||
| Potential Upside | 77.4 | |||
| Downside Variance | 723.04 | |||
| Semi Variance | 380.59 | |||
| Expected Short fall | (32.55) | |||
| Skewness | 1.82 | |||
| Kurtosis | 5.64 |
Consider Estrella Immunopharma's intraday indicators
Estrella Immunopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Estrella Immunopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.68 | |||
| Day Median Price | 0.052 | |||
| Day Typical Price | 0.052 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) |
Estrella Stock media impact
Far too much social signal, news, headlines, and media speculation about Estrella Immunopharma that are available to investors today. That information is available publicly through Estrella media outlets and privately through word of mouth or via Estrella internal channels. However, regardless of the origin, that massive amount of Estrella data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Estrella Immunopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Estrella Immunopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Estrella Immunopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Estrella Immunopharma alpha.
Estrella Immunopharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Estrella Immunopharma stock to make a market-neutral strategy. Peer analysis of Estrella Immunopharma could also be used in its relative valuation, which is a method of valuing Estrella Immunopharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Additional Tools for Estrella Stock Analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.